Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Linsitinib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Linsitinib?

Linsitinib is an investigational drug.

There have been 8 clinical trials for Linsitinib. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2009.

The most common disease conditions in clinical trials are Carcinoma, Adenocarcinoma, and Paraganglioma. The leading clinical trial sponsors are National Cancer Institute (NCI), Astellas Pharma Inc, and Oxford University Hospitals NHS Trust.

Recent Clinical Trials for Linsitinib
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib TrialAstellas Pharma Global Development, Inc.Phase 2
Eurosarc Trial of Linsitinib in Advanced Ewing SarcomaAstellas Pharma IncPhase 2
Eurosarc Trial of Linsitinib in Advanced Ewing SarcomaEuropean CommissionPhase 2

See all Linsitinib clinical trials

Clinical Trial Summary for Linsitinib

Top disease conditions for Linsitinib
Top clinical trial sponsors for Linsitinib

See all Linsitinib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.